Evaluation of oxidative stress in patients of follicular thyroid cancer and study the therapeutic effect of resveratrol on oxidativstress in FTC-133 thyroid cancer cell line

Abstract

The second most common cancer of the Thyroid gland is FollicularThyroid Carcinoma (FTC), second only to papillary carcinoma. Resveratrol, a natural polyphenolic compound that has anti-oxidative, anti-inflammatory and apoptotic properties, appears to have substantial cardioprotection and cancer-prevention properties. Furthermore, resveratrol is thought to be responsible for regulating several biological processes, such as metabolism and aging, through the modulation of the mammalian silent information regulator 1 (SIRT1) of the Sirtuins family. The purpose of this study is evaluating erythrocyte malondialdehyde’s (MDA) role in the indication of the oxidative status in follicular thyroid carcinoma patients and investigating the therapeutic effect of resveratrol, a potent antioxidant, upon oxidative stress levels in thyroid cancer in vitro. Malondialdehyde was evaluated in erythrocyte of follicular thyroid cancer patients after and before treatment with sodium stibogluconate. Cytotoxicity by MTT assay and intracellular reactive oxygen species (ROS) levels was measured after resveratrol treatment on follicular thyroid carcinoma FTC-133 cell line. The results of this study confirmed that150 μM Resveratrol inhibited proliferation of FTC-133 thyroid cancer cell line in vitro by 88% after 72hand treatment with 50-200μM Resveratrol reduced ROS levels. To sum up, considering its mode of action, resveratrol might have an important role in providing a source for natural antitumor agents, a fact that would have great therapeutic potential in integrated oncology.